TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Director and Officer Rule 10b5-1 Trading Arrangements
During the fiscal quarter ended September 30, 2026, each of the following officers adopted a Rule 10b5-1 trading arrangement (as such term is defined in Item 408 of Regulation S-K). All trading plans are intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
| Name and Title | Date | Expiration Date | Maximum Shares Subject to Plan (1) |
|---|---|---|---|
| Christine Fox, EVP, U.S. Commercial | August 4, 2026 | November 21, 2026 | 63,492 |
| Matthew Shields, EVP, Teva Global Operations | August 4, 2026 | June 5, 2027 | 171,410 |
| Dr. Eric Hughes, EVP, Global R&D and Chief Medical Officer | September 1, 2026 | March 8, 2027 | 266,477 |
(1) Certain plans include shares to be sold solely to cover tax withholding obligations.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.